Moderna completes enrollment in mid-stage study of COVID-19 vaccine

In a post on social media, Moderna (MRNA +2.0%) announces that it has completed enrollment in a Phase 2 clinical trial evaluating the safety, reactogenicity and immunogenicity of COVID-19 vaccine candidate mRNA-1273 in 600 healthy volunteers across two age cohorts: 18-55 years old and 55+ years old.

A Phase 3 study should launch this month.

Enrollment in cohorts of older adults (56-70 years old and 71+) in an NIH-led Phase 1 trial has been completed.

Company remains on track to deliver ~500M doses/year with an upside to 1B doses/year beginning in 2021.

Selected COVID-19 vaccine players: Novavax (NVAX -1.5%), Dynavax Technologies (DVAX +6.3%), GlaxoSmithKline (GSK +0.8%), Merck (MRK +0.0%), Sanofi (SNY +0.1%), Inovio Pharmaceuticals (INO -4.0%), iBio (IBIO +5.8%), Arcturus Therapeutics (ARCT +0.4%), Soligenix (SNGX +2.0%), GeoVax Labs (OTCQB:GOVX -2.3%), Vaxart (VXRT -9.5%), Altimmune (ALT +2.9%), Vir Biotechnology (VIR +6.3%), Pfizer (PFE +0.7%), BioNTech (BNTX -2.6%), AstraZeneca (AZN +1.1%)

https://seekingalpha.com/news/3589490-moderna-completes-enrollment-in-mid-stage-study-of-covidminus-19-vaccine